Opko Health Inc. (NASDAQ:OPK) CEO Purchases $106,000.00 in Stock

Share on StockTwits

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were purchased at an average cost of $2.12 per share, for a total transaction of $106,000.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $6,506,176.12. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, July 12th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were purchased at an average cost of $2.16 per share, for a total transaction of $108,000.00.
  • On Monday, July 8th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The stock was bought at an average cost of $2.23 per share, for a total transaction of $223,000.00.
  • On Tuesday, July 2nd, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $2.42 per share, for a total transaction of $121,000.00.
  • On Tuesday, June 25th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The stock was bought at an average cost of $2.01 per share, for a total transaction of $201,000.00.
  • On Thursday, June 20th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $2.04 per share, for a total transaction of $102,000.00.
  • On Tuesday, June 18th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $2.02 per share, for a total transaction of $101,000.00.
  • On Thursday, June 13th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.92 per share, for a total transaction of $96,000.00.
  • On Tuesday, June 11th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.87 per share, for a total transaction of $93,500.00.
  • On Friday, June 7th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.87 per share, for a total transaction of $93,500.00.
  • On Wednesday, June 5th, Phillip Md Et Al Frost acquired 150,000 shares of Opko Health stock. The stock was bought at an average cost of $1.92 per share, for a total transaction of $288,000.00.

Shares of OPK stock opened at $2.08 on Friday. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -8.32 and a beta of 2.14. The company has a current ratio of 1.10, a quick ratio of 0.99 and a debt-to-equity ratio of 0.13. Opko Health Inc. has a 52 week low of $1.73 and a 52 week high of $6.16. The stock has a 50-day moving average of $2.08.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.08). Opko Health had a negative net margin of 19.92% and a negative return on equity of 9.86%. The business had revenue of $222.50 million during the quarter, compared to the consensus estimate of $241.27 million. During the same period last year, the firm earned ($0.08) EPS. The business’s revenue for the quarter was down 12.7% on a year-over-year basis. As a group, analysts expect that Opko Health Inc. will post -0.42 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of OPK. Norges Bank bought a new stake in shares of Opko Health in the fourth quarter valued at approximately $9,207,000. Marshall Wace LLP raised its position in shares of Opko Health by 3,541.3% in the first quarter. Marshall Wace LLP now owns 1,452,176 shares of the biotechnology company’s stock valued at $3,099,000 after purchasing an additional 1,412,295 shares during the period. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its position in shares of Opko Health by 98.4% in the second quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 2,092,606 shares of the biotechnology company’s stock valued at $5,106,000 after purchasing an additional 1,037,669 shares during the period. Jane Street Group LLC raised its position in shares of Opko Health by 484.5% in the fourth quarter. Jane Street Group LLC now owns 531,514 shares of the biotechnology company’s stock valued at $1,600,000 after purchasing an additional 440,572 shares during the period. Finally, BlackRock Inc. raised its position in shares of Opko Health by 1.4% in the fourth quarter. BlackRock Inc. now owns 30,276,662 shares of the biotechnology company’s stock valued at $91,133,000 after purchasing an additional 408,951 shares during the period. 25.35% of the stock is currently owned by institutional investors.

Several analysts have commented on the stock. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Zacks Investment Research lowered shares of German American Bancorp. from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Opko Health presently has a consensus rating of “Buy” and a consensus target price of $9.25.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Further Reading: Tariff

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Strategic Wealth Partners Ltd. Sells 294 Shares of FirstEnergy Corp.
Strategic Wealth Partners Ltd. Sells 294 Shares of FirstEnergy Corp.
Vanguard Real Estate ETF  Shares Sold by Strategic Wealth Partners Ltd.
Vanguard Real Estate ETF Shares Sold by Strategic Wealth Partners Ltd.
SPDR Portfolio Long Term Treasury ETF  Shares Sold by Strategic Wealth Partners Ltd.
SPDR Portfolio Long Term Treasury ETF Shares Sold by Strategic Wealth Partners Ltd.
Strategic Wealth Partners Ltd. Sells 2,592 Shares of ISHARES TR/CORE U S REIT ETF
Strategic Wealth Partners Ltd. Sells 2,592 Shares of ISHARES TR/CORE U S REIT ETF
Strategic Wealth Partners Ltd. Lowers Stock Holdings in Diageo plc
Strategic Wealth Partners Ltd. Lowers Stock Holdings in Diageo plc
Strategic Wealth Partners Ltd. Sells 11,768 Shares of iShares US Real Estate ETF
Strategic Wealth Partners Ltd. Sells 11,768 Shares of iShares US Real Estate ETF


© 2006-2019 Ticker Report